Pluristem Receives Regulatory Korean Approval to Extend Phase II Study of PLX-PAD Cells for Treatment of IC

By: Benzinga
Pluristem Therapeutics (NASDAQ: PSTI ) announced today that the South Korean Ministry of Food and Drug Safety (MFDS), formerly the Korea Food & Drug Administration (KFDA), has approved Pluristem's Investigational New Drug (IND) Application to conduct a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.